Report cover image

Lipoxygenase Inhibitors - Pipeline Insight, 2025

Publisher DelveInsight
Published Apr 01, 2025
Length 80 Pages
SKU # DEL19993603

Description

DelveInsight’s, “Lipoxygenase Inhibitor (LOX Inhibitor) - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipoxygenase Inhibitor (LOX Inhibitor) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Lipoxygenase Inhibitor (LOX Inhibitor) Understanding

Lipoxygenase Inhibitor (LOX Inhibitor): Overview

Lipoxygenase (LOX) is a kind of rate-limiting enzyme in the process of arachidonic acid metabolism into leukotriene (LT) which mediates the occurrence of inflammation. The inhibition of LOX can reduce LT, thereby producing an anti-inflammatory effect. Lipoxygenase (LOX) can catalyze fatty acid to produce a number of active metabolic products that are involved in a lot of vital diseases. For instance, type 1 and type 2 diabetes (or both), cardiovascular diseases, hypertension, renal diseases, and neurological conditions such as Alzheimer's disease and Parkinson's disease.

LOX inhibitors are developed more slowly than COX inhibitors due to a lack of specific structure of LOXs. Additionally, as a result of the coexistence of LOXs in the same organism, LOX inhibitors should be designed seriously so as to achieve the targeting effect. In particular, another regulatory domain that is different from the two known domains of the C-terminal catalytic domain and the N-terminal β-barrel domain has been found, which will provide new ideas for the design of new LOX inhibitors.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Lipoxygenase Inhibitor (LOX Inhibitor) R&D. The therapies under development are focused on novel approaches for Lipoxygenase Inhibitor (LOX Inhibitor).
Lipoxygenase Inhibitor (LOX Inhibitor) Emerging Drugs Chapters

This segment of the Lipoxygenase Inhibitor (LOX Inhibitor) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lipoxygenase Inhibitor (LOX Inhibitor) Emerging Drugs
  • Epeleuton: Afimmune
Epeleuton, previously named DS102, is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a second-generation synthetic n-3 fatty acid and derivative of an endogenous downstream metabolite of EPA. Epeleuton is a new chemical entity with additional therapeutic effects compared with other n-3 fatty acid. It acts as 5-Lipoxygenase Inhibitor (LOX Inhibitor) and is currently in Phase II of clinical trial for Alcoholic hepatitis, Chronic obstructive pulmonary disease, Diabetic neuropathies, Hypertriglyceridaemia, Idiopathic pulmonary fibrosis, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Type 2 diabetes mellitus.
  • Tipelukast: MediciNova
Tipelukast is being developed by MediciNova and is in Phase II forIdiopathic pulmonary fibrosis, Non-alcoholic steatohepatitis. It acts as 5-Lipoxygenase Inhibitor (LOX Inhibitor).

Further product details are provided in the report……..

Lipoxygenase Inhibitor (LOX Inhibitor): Therapeutic Assessment

This segment of the report provides insights about the different Lipoxygenase Inhibitor (LOX Inhibitor) drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Lipoxygenase Inhibitor (LOX Inhibitor)
There are approx. 10+ key companies which are developing the Lipoxygenase Inhibitor (LOX Inhibitor). The companies which have their Lipoxygenase Inhibitor (LOX Inhibitor) drug candidates in the most advanced stage, i.e. phase II include, Afimmune.
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Lipoxygenase Inhibitor (LOX Inhibitor) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lipoxygenase Inhibitor (LOX Inhibitor): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lipoxygenase Inhibitor (LOX Inhibitor) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lipoxygenase Inhibitor (LOX Inhibitor) drugs.

Lipoxygenase Inhibitor (LOX Inhibitor) Report Insights
  • Lipoxygenase Inhibitor (LOX Inhibitor) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Lipoxygenase Inhibitor (LOX Inhibitor) Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Lipoxygenase Inhibitor (LOX Inhibitor) drugs?
  • How many Lipoxygenase Inhibitor (LOX Inhibitor) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Lipoxygenase Inhibitor (LOX Inhibitor)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lipoxygenase Inhibitor (LOX Inhibitor) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lipoxygenase Inhibitor (LOX Inhibitor) and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Afimmune
  • MediciNova
  • Mariposa Health Limited
  • MedWell Laboratories
  • BioElectron Technology
  • CSPC Ouyi Pharmaceutical
  • Veralox Therapeutics
  • Qurient Therapeutics
Key Products
  • Epeleuton
  • Tipelukast
  • TA 270
  • MW 001
  • PTC 857
  • Baicalein
  • VLX 1005
  • Research programme: 5-Lipoxygenase Inhibitor (LOX Inhibitor)

Table of Contents

80 Pages
Introduction
Executive Summary
Lipoxygenase Inhibitor (LOX Inhibitor): Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Lipoxygenase Inhibitor (LOX Inhibitor) - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Lipoxygenase Inhibitor (LOX Inhibitor) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Lipoxygenase Inhibitor (LOX Inhibitor) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Epeleuton: Afimmune
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PTC 857: BioElectron Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
VLX 1005: Veralox Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Lipoxygenase Inhibitor (LOX Inhibitor) Key Companies
Lipoxygenase Inhibitor (LOX Inhibitor) Key Products
Lipoxygenase Inhibitor (LOX Inhibitor)- Unmet Needs
Lipoxygenase Inhibitor (LOX Inhibitor)- Market Drivers and Barriers
Lipoxygenase Inhibitor (LOX Inhibitor)- Future Perspectives and Conclusion
Lipoxygenase Inhibitor (LOX Inhibitor) Analyst Views
Lipoxygenase Inhibitor (LOX Inhibitor) Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us